Early intervention needs to be a ‘team sport’ to curb checkpoint inhibitor-related irAEs

Early intervention is critical in managing patients with immune-related adverse events associated with cancer checkpoint inhibitor therapy, according to a presenter at the 2020 Interdisciplinary Autoimmune Summit.“This is something that all of us will be drawn into in the near-term future,” Leonard H. Calabrese, DO, chief medical editor of Healio Rheumatology, and professor of medicine, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, said in his presentation. “It is not one disease, it is many diseases.”Calabrese warned that all organRead More

Share on facebook
Share on twitter
Share on linkedin